巨子生物-运营滑坡：研发实力 + 高利润率提供缓冲
GIANT BIOGENEGIANT BIOGENE(HK:02367)2025-12-17 03:01

December 16, 2025 04:09 PM GMT Giant Biogene | Asia Pacific Operating Slippage Buffered By R&D Strength + High Margins | What's Changed | | | | --- | --- | --- | | Giant Biogene Holding Co Ltd (2367.HK) | From | To | | Price Target | HK$78.00 | HK$42.00 | The challenges facing GB are resolvable. Its strong margins allow for increased marketing spend to restore brand momentum, and its robust ingredient R&D supports a healthy product pipeline. Operational improvements remain the key driver for sales growth an ...